Source: PR NEWSWIRE

Press Release: Avid Radiopharmaceuticals : New Study Shows Florbetapir F 18 Injection Scans Led to Change in Diagnosis and Management of Patients Being Evaluated for Cognitive Decline

INDIANAPOLIS, July 22, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced new data showing that knowledge of amyloid status as determined by Florbetapir F 18 Injection imaging altered diagnosis...

Read full article »
Est. Annual Revenue
$5.0-25M
Agree?
Est. Employees
100-250
Agree?
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100



Avid Radiopharmaceuticals, Inc., is a Private company. Avid Radiopharmaceuticals, Inc.,'s parent company has been Lilly Eli & Co since Dec 2011.